The company said the drug showed up to 19% weight loss after 46 weeks in a mid-stage trial.
Blue Shield, whose health plans cover 4.8 million members, said it will now work with five different companies, including Mark Cuban’s drug company, to provide “convenient, transparent access to medications while lowering costs.”
After two prior setbacks, the regulator has finally approved Ipsen’s palovarotene to treat fibrodysplasia ossificans progressiva. It’s the first treatment for the ultra-rare bone disease.
Yesterday the company announced positive results from two early-stage clinical trials for its first in-class small molecule imipridone, a potential treatment for an incurable and aggressive type of pediatric brain tumor which demonstrated longer survival in this subset of patients.
Mifepristone’s legal saga continues as the U.S. 5th Circuit Court of Appeals ruled for steep restrictions on the drug’s access, though its effectivity is pending the Supreme Court’s review.
Linde is seeking protection over confidential information and trade secrets.
Nine U.S. states are objecting to a proposed $13.5 million settlement between Eli Lilly and a class of insulin buyers over claims that it inflated the drug’s price, saying the drugmaker is wrongly trying to use the deal to shield itself from future lawsuits by states.
The regulator informed bluebird bio that it will not convene an advisory committee meeting to discuss the company’s application for the gene therapy being developed for sickle cell disease.
Following a nearly decade-long effort, Delcath Systems finally won the FDA’s greenlight for its Hepzato Kit for the liver-directed treatment of adult patients with metastatic uveal melanoma.
Amid strong performance in the first half of 2023, Stada Arzneimittel’s private equity owners are considering a potential sale, though there are still no definite plans, according to CEO Peter Goldschmidt.
